Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Standard of Care: Surgery and Targeted Therapy

At a Glance

The standard treatment for localized Gastrointestinal Stromal Tumors (GIST) is surgical removal. For larger tumors or advanced disease, targeted therapies called Tyrosine Kinase Inhibitors (TKIs), such as imatinib, are used to shrink tumors and specifically block cancer cell growth.

The treatment of GIST has undergone a dramatic transformation over the last two decades. While surgery remains a cornerstone of care, the discovery of targeted therapies has turned a once-difficult-to-treat cancer into a manageable condition for many patients [1][2].

The Role of Surgery

For most patients with a localized GIST (a tumor that has not spread), surgery is the primary treatment [3]. The goal is a complete removal of the tumor with “clear margins,” meaning no cancer cells are left at the edges of the surgical site [4]. Because GISTs are often fragile, surgeons take great care to avoid tumor rupture, which can spread cancer cells throughout the abdomen [5].

Neoadjuvant Therapy: Shrinking the Tumor

In some cases, a surgeon may recommend starting medication before surgery. This is called neoadjuvant therapy [3]. This approach is often used when:

  • The tumor is very large [6].
  • The tumor is in a difficult location, such as the rectum or the top of the stomach [7].
  • Surgery would be highly invasive or might require removing part of a nearby organ [8].

By taking a TKI (usually imatinib) for several months, the tumor can shrink, making the eventual surgery smaller, safer, and more effective [9][10].

Targeted Therapy vs. Traditional Chemo

It is important to understand that GIST medications are not traditional chemotherapy [11].

  • Traditional Chemotherapy: Works by attacking all fast-growing cells in the body, which often causes side effects like hair loss and severe nausea [11].
  • Targeted Therapy (TKIs): These are Tyrosine Kinase Inhibitors. They act like a specific “key” that fits into the broken “lock” (the mutation) on the cancer cell [12]. By blocking the signal that tells the cell to grow, these drugs can stop or shrink the tumor without affecting most healthy cells [1].

The Importance of the D842V Mutation

Mutation testing is not just a formality—it dictates which drug you receive. A specific mutation called PDGFRA D842V is naturally resistant to the standard drug, imatinib [13]. For patients with this specific mutation, a newer drug called avapritinib is used because it was designed to target that exact “stuck switch” [14][15].

Note on Avapritinib: Because avapritinib crosses into the brain differently than other TKIs, it carries unique side effects, including neurological risks like cognitive impairment, memory issues, or central nervous system toxicity. Patients taking this drug require careful monitoring by their care team [16].

Sequence of Treatment for Advanced GIST

If GIST has spread or if it becomes resistant to the first medication, doctors follow a standardized sequence of “lines” of therapy. Each new line is designed to overcome the ways the cancer has learned to bypass the previous drug [17]:

  1. First-Line: Imatinib (Gleevec) — The standard starting point for most patients [11].
  2. Second-Line: Sunitinib (Sutent) — Used if imatinib stops working or causes too many side effects [18].
  3. Third-Line: Regorafenib (Stivarga) — An option for those who have tried the first two drugs [19].
  4. Fourth-Line: Ripretinib (Qinlock) — A “switch-control” inhibitor designed to block multiple types of resistance [20][21].

This “relay race” of medications allows many patients to maintain a high quality of life for many years, even with advanced disease [2][1].

Common questions in this guide

What is the main treatment for a localized GIST?
For most patients with a localized GIST, surgery is the primary treatment. The goal is the complete removal of the tumor with clear margins to ensure no cancer cells are left behind.
Why might I need to take medication before my GIST surgery?
Taking a targeted therapy drug before surgery is called neoadjuvant therapy. This approach is used to shrink very large or difficult-to-reach tumors, making the eventual surgery safer and less invasive.
How is GIST targeted therapy different from traditional chemotherapy?
Traditional chemotherapy attacks all fast-growing cells, causing broad side effects. Targeted therapies, like Tyrosine Kinase Inhibitors (TKIs), act like a specific key to block the exact signals that tell GIST cancer cells to grow, largely sparing healthy cells.
What treatment is used for a GIST with the PDGFRA D842V mutation?
GISTs with the PDGFRA D842V mutation are naturally resistant to the standard drug imatinib. Instead, a newer targeted therapy called avapritinib is used because it was specifically designed to target this exact mutation.
What happens if my GIST stops responding to imatinib?
If your tumor becomes resistant to your first medication, doctors follow a standardized sequence of backup targeted therapies. The second-line therapy is typically sunitinib, which can be followed by regorafenib and ripretinib if the cancer learns to bypass previous drugs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my tumor a candidate for neoadjuvant imatinib to shrink it before surgery?
  2. 2.Given my specific mutation profile, which TKI is the most effective first-line treatment for me?
  3. 3.If my tumor develops resistance to imatinib in the future, what is the planned sequence for second-, third-, and fourth-line therapies?
  4. 4.How will we monitor the effectiveness of the medication—through CT scans, PET scans, or other imaging?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.

    Huang WK, Wu CE, Wang SY, et al.

    Current treatment options in oncology 2022; (23(9)):1303-1319 doi:10.1007/s11864-022-00996-8.

    PMID: 35976553
  2. 2

    Gastrointestinal Stromal Tumors.

    von Mehren M, Joensuu H

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(2)):136-143 doi:10.1200/JCO.2017.74.9705.

    PMID: 29220298
  3. 3

    Giant gastric gastrointestinal stromal tumor: A case report.

    Neupane D, Pandit N

    International journal of surgery case reports 2025; (131()):111420 doi:10.1016/j.ijscr.2025.111420.

    PMID: 40393363
  4. 4

    Resection of GIST in the duodenum and proximal jejunum: A retrospective analysis of outcomes.

    Huang Y, Chen G, Lin L, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019; (45(10)):1950-1956 doi:10.1016/j.ejso.2019.05.002.

    PMID: 31085027
  5. 5

    Defining Tumor Rupture in Gastrointestinal Stromal Tumor.

    Nishida T, Hølmebakk T, Raut CP, Rutkowski P

    Annals of surgical oncology 2019; (26(6)):1669-1675 doi:10.1245/s10434-019-07297-9.

    PMID: 30868512
  6. 6

    [A Case Report of a Giant GIST Markedly Responsive to Neoadjuvant Chemotherapy with Imatinib Mesylate].

    Irie T, Kawai M, Takahashi H, et al.

    Gan to kagaku ryoho. Cancer & chemotherapy 2022; (49(13)):1983-1985.

    PMID: 36733065
  7. 7

    [A Case of the Large Rectal GIST Treated by Laparoscopic Anus Preserving Operation after Neoadjuvant Therapy with Imatinib Mesylate].

    Matsuzuka S, Iseki Y, Fukuoka T, et al.

    Gan to kagaku ryoho. Cancer & chemotherapy 2021; (48(3)):385-387.

    PMID: 33790163
  8. 8

    Gastrointestinal stromal tumor of the rectum resected by transanal total mesorectal excision after neoadjuvant imatinib treatment: A case report.

    Yano T, Nakahara M, Okuda H, et al.

    Asian journal of endoscopic surgery 2020; (13(4)):574-577 doi:10.1111/ases.12782.

    PMID: 32017449
  9. 9

    Pretreatment Tumor DNA Sequencing of KIT and PDGFRA in Endosonography-Guided Biopsies Optimizes the Preoperative Management of Gastrointestinal Stromal Tumors.

    Hedenström P, Andersson C, Sjövall H, et al.

    Molecular diagnosis & therapy 2020; (24(2)):201-214 doi:10.1007/s40291-020-00451-0.

    PMID: 32124386
  10. 10

    [A Case of a Giant Rectal GIST Markedly Responsive to Neoadjuvant Chemotherapy with Imatinib Mesylate].

    Yamamoto M, Kato K, Hayashi K, et al.

    Gan to kagaku ryoho. Cancer & chemotherapy 2024; (51(13)):1564-1566.

    PMID: 39948925
  11. 11

    Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.

    Bauer S, Joensuu H

    Drugs 2015; (75(12)):1323-34 doi:10.1007/s40265-015-0440-8.

    PMID: 26187774
  12. 12

    Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.

    Bauer S, George S, von Mehren M, Heinrich MC

    Frontiers in oncology 2021; (11()):672500 doi:10.3389/fonc.2021.672500.

    PMID: 34322383
  13. 13

    Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.

    Smrke A, Gennatas S, Huang P, Jones RL

    Future oncology (London, England) 2020; (16(22)):1639-1646 doi:10.2217/fon-2020-0348.

    PMID: 32517495
  14. 14

    Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.

    Henriques-Abreu M, Serrano C

    Expert review of anticancer therapy 2021; (21(10)):1081-1088 doi:10.1080/14737140.2021.1963235.

    PMID: 34404327
  15. 15

    Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA.

    Teuber A, Schulz T, Fletcher BS, et al.

    Nature communications 2024; (15(1)):63 doi:10.1038/s41467-023-44376-8.

    PMID: 38167404
  16. 16

    Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.

    Huang W, Yuan W, Ren L, et al.

    Pathology, research and practice 2022; (239()):154138 doi:10.1016/j.prp.2022.154138.

    PMID: 36183438
  17. 17

    Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Blay JY, Serrano C, Heinrich MC, et al.

    The Lancet. Oncology 2020; (21(7)):923-934 doi:10.1016/S1470-2045(20)30168-6.

    PMID: 32511981
  18. 18

    Targeting gastrointestinal stromal tumors: the role of regorafenib.

    Schroeder B, Li Z, Cranmer LD, et al.

    OncoTargets and therapy 2016; (9()):3009-16 doi:10.2147/OTT.S104081.

    PMID: 27284251
  19. 19

    An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.

    Schvartsman G, Wagner MJ, Zobniw CM, et al.

    Current oncology reports 2016; (18(8)):49 doi:10.1007/s11912-016-0536-7.

    PMID: 27319943
  20. 20

    Ripretinib for the treatment of advanced gastrointestinal stromal tumor.

    Zalcberg JR

    Therapeutic advances in gastroenterology 2021; (14()):17562848211008177 doi:10.1177/17562848211008177.

    PMID: 33948116
  21. 21

    Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib.

    Brackert S, Polson K

    Journal of the advanced practitioner in oncology 2023; (14(4)):317-328 doi:10.6004/jadpro.2023.14.4.6.

    PMID: 37313282

This page provides educational information about GIST surgical and targeted treatment options. It is not a substitute for professional medical advice; always discuss your specific treatment plan and medication side effects with your oncology team.

Get notified when new evidence is published on Gastrointestinal stromal tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.